Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 244 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo in clinic Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Examine the Effects of Oral Fenretinide

NCT06528457
View directory record Official record
Conditions
Dengue
Interventions
ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo
Drug · Other
Lead sponsor
Island Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751098
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention

NCT02896712
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Acceptance and Commitment Therapy (ACT), Drug Counseling (DC), Contingency Management (CM), Placebo, Modafinil
Behavioral · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

NCT04196101
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Pelham, Alabama • Anaheim, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Not applicable Interventional

Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research

NCT01900288
View directory record Official record
Conditions
Short Bowel Syndrome, Malabsorption, Malnutrition
Interventions
HPN Group Clinic Appointments using Mobile Devices (experimental), Mobile Device Access (placebo)
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
13 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder Functional Outcomes

NCT02588027
View directory record Official record
Conditions
Rotator Cuff Tear Arthropathy
Interventions
Ibuprofen, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Early Phase 1 Interventional Results available

Sildenafil To Prevent Clot

NCT03199612
View directory record Official record
Conditions
Thrombosis, Hemolysis
Interventions
Sildenafil, Placebo Oral Tablet
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

NCT03362177
View directory record Official record
Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
Romiplostim, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
22
States / cities
Jonesboro, Arkansas • Anaheim, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Program for Alleviating and Resolving Trauma and Stress 2

NCT05095428
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
PARTS Program, NBSR-T Program
Behavioral
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds

NCT04095104
View directory record Official record
Conditions
Obesity, Morbid, Bariatric Surgery, Adolescent, Young Adult, Drug Therapy
Interventions
Phentermine, Immediate Release Topiramate, Placebo for Phentermine, Placebo for Immediate Release Topiramate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)

NCT01027884
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne, Ambulatory Care
Interventions
Placebo, Idebenone
Drug
Lead sponsor
Santhera Pharmaceuticals
Industry
Eligibility
10 Years to 18 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

NCT01263223
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of SRP-4053 in DMD Patients

NCT02310906
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Placebo, SRP-4053
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
6 Years to 15 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 13, 2026, 5:49 PM EDT
Terminated Phase 4 Interventional Results available

The Use of Intranasal Ketoralac for Pain Management (Sprix)

NCT01736358
View directory record Official record
Conditions
Postoperative Pain Management, Urolithiasis
Interventions
Intranasal Ketoralac, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

NCT02555878
View directory record Official record
Conditions
Neoplasms
Interventions
Rivaroxaban, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
70
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 13, 2026, 5:49 PM EDT
Withdrawn Phase 2 Interventional

Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI

NCT02148367
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Erythropoietin
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

NCT03769116
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
delandistrogene moxeparvovec, placebo
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

NCT01645787
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
4-aminopyridine, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

NCT00739973
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Games to Overcome Late Life Depression

NCT02229188
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Problem Solving Therapy, Evolution, Words
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Chlorthalidone in Chronic Kidney Disease

NCT02841280
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hypertension
Interventions
Chlorthalidone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Not applicable Interventional

Community-Based Screening for Chronic Kidney Disease

NCT07747363
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
outpatient clinic kidney-protective care
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 13, 2026, 5:49 PM EDT